(Date:5/18/2012)... clears the mind. It gets the blood pumping and ... familiar territory, but Dartmouth,s David Bucci thinks there is ... years there have been data suggesting that neurobiological changes ... here," says Bucci, an associate professor in the Department ... Bucci and his collaborators have revealed important new findings: ...
(Date:5/17/2012)... increasing opportunities to participate in genetic testing that ... a disease. Receiving these results does not appreciably ... potentially costly follow-up health services, according to a ... of Health and colleagues at other institutions. , ... online issue of Genetics in Medicine ...
(Date:5/17/2012)... May 17th 2012. Wiley-Blackwell, the scientific, technical, medical ... Inc., today announced the launch of Food Science ... Access publishing program. The journal will provide authors with ... latest research and will be published in collaboration with ... Science & Technology and other prominent societies. , ...
Breaking Biology News(10 mins):Dartmouth researchers are learning how exercise affects the brain 2Dartmouth researchers are learning how exercise affects the brain 3NIH-led study finds genetic test results do not trigger increased use of health services 2NIH-led study finds genetic test results do not trigger increased use of health services 3NIH-led study finds genetic test results do not trigger increased use of health services 4Wiley-Blackwell launches new open-access journal: Food Science & Nutrition 2Black Liver Cancer Patients Face Worst Odds 65074 1Black Liver Cancer Patients Face Worst Odds 65074 2GNC Becomes a Presenting Sponsor for the Pittsburgh Health 26amp 3B Fitness Expo of the Dicks Sporting Goods Pittsburgh Marathon 65070 1GNC Becomes a Presenting Sponsor for the Pittsburgh Health 26amp 3B Fitness Expo of the Dicks Sporting Goods Pittsburgh Marathon 65070 2GNC Becomes a Presenting Sponsor for the Pittsburgh Health 26amp 3B Fitness Expo of the Dicks Sporting Goods Pittsburgh Marathon 65070 3 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 1 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 2 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 3 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 4 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 5 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 6 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 7 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 8 C6terna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized Double Blind Placebo Co 15396 9(Date:5/16/2012)... YORK, May 16, 2012 ... research report is available in its ... Industry http://www.reportlinker.com/p090668/Global-Biotechnology-Instrumentation-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_ ... worldwide markets for Biotechnology Instrumentation in ... Segments: DNA Synthesizers, Protein/Peptide Synthesizers, DNA ...
(Date:5/16/2012)... May 16, 2012 MultiCell Technologies, Inc. ... is pleased to announce representatives from the ... MCT-465 and MCT-485 at CIMT 2012 ( ... cancer immunotherapy research and development. CIMT 2012 ... Mainz, Germany. The title of the poster ...
(Date:5/15/2012)... Vermillion, Inc. (NASDAQ: VRML ), a leading ... the first quarter ended March 31, 2012. ... the volume of OVA1®, the company,s flagship diagnostic test ... was generally in line with the forecast set by ... 28% to 3,952 from the same year-ago quarter. ...
(Date:5/15/2012)... -- Cardium Therapeutics (NYSE Amex: CXM ... first quarter ended March 31, 2012, and other ... In addition to the announcement ... its goals for 2012, which were outlined in ... advance commercialization of its new Excellagen® advanced, physician-use ...
Breaking Biology Technology:Global Biotechnology Instrumentation Industry 2Global Biotechnology Instrumentation Industry 3Global Biotechnology Instrumentation Industry 4Global Biotechnology Instrumentation Industry 5Global Biotechnology Instrumentation Industry 6Global Biotechnology Instrumentation Industry 7Global Biotechnology Instrumentation Industry 8Global Biotechnology Instrumentation Industry 9Global Biotechnology Instrumentation Industry 10Global Biotechnology Instrumentation Industry 11Global Biotechnology Instrumentation Industry 12Global Biotechnology Instrumentation Industry 13Global Biotechnology Instrumentation Industry 14Global Biotechnology Instrumentation Industry 15Global Biotechnology Instrumentation Industry 16Global Biotechnology Instrumentation Industry 17Global Biotechnology Instrumentation Industry 18Global Biotechnology Instrumentation Industry 19Global Biotechnology Instrumentation Industry 20MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 2MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 3MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 4MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 5Vermillion Reports First Quarter 2012 Results 2Vermillion Reports First Quarter 2012 Results 3Vermillion Reports First Quarter 2012 Results 4Vermillion Reports First Quarter 2012 Results 5Vermillion Reports First Quarter 2012 Results 6Vermillion Reports First Quarter 2012 Results 7Vermillion Reports First Quarter 2012 Results 8Cardium Presents First Quarter 2012 Financial Results and Recent Developments 2Cardium Presents First Quarter 2012 Financial Results and Recent Developments 3Cardium Presents First Quarter 2012 Financial Results and Recent Developments 4Cardium Presents First Quarter 2012 Financial Results and Recent Developments 5Cardium Presents First Quarter 2012 Financial Results and Recent Developments 6... Inc., the pioneer,in scalable, high performance cell loading ... Demonstration of the MaxCyte STX Scalable,Transfection System on ... the,A/C/T Assays & Cellular Targets Conference in San ... Vice President of Research and,Development at MaxCyte, "The ...
... has,announced the launch of a new "Nursing School" section ... portal section is designed to assist,nursing school educators in ... assist students with research promoting patient safety,patient handling and ... is a pro bono injury prevention,site designed to help ...
... Helix BioPharma announced,today that Dr. Heman Chao, ... be presenting L-DOS47 research findings at the National,Research ... of the,Genomics and Health Initiative, today in Saskatoon, ... the NRC, government,departments and private industry and covers ...
Other Biology Technology:MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting 2New Safe Lifting Patient Safety Resource for Nursing School Educators and Students 2Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada 2Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada 3Hybridization Buffer 3.6 ml...
...
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products:Biology NavigationMedical Navigation